News | March 03, 2022
Merck KGaA reports higher profits on strong volumes across its businesses
Company expects strong organic growth in sales, EBITDA in 2022
Company expects strong organic growth in sales, EBITDA in 2022
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
TruPharma has commenced commercial marketing of Sage's approved generic cartridge product
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
In a European work-sharing procedure (WSP), Glucophage was approved as the first oral anti-diabetic medication to be used safely from conception to birth
Subscribe To Our Newsletter & Stay Updated
